Search Results
Sep 17, 2025, 06:00 ET Retail Logistics Market Growing at over 5.52% CAGR by 2030, Amid Global Supply Chain Transformation | Mordor Intelligence
companies include: DHL Supply Chain & Global Forwarding UPS Supply Chain Solutions FedEx Logistics XPO Logistics Kuehne + Nagel International C.H. Robinson Worldwide JD Logistics Cainiao (Alibaba Logistics) SF
More news about: Mordor Intelligence Private Limited
Sep 11, 2025, 06:00 ET BizClik Launches September 2025 Editions Across 8 Leading Industry Magazines
Horn discuss unlocking the supply chain's first mile,this issue also spotlights the industry's leading events, from the Gartner Supply Chain Symposium/Xpo to Procurement & Supply Chain LIVE and SAP Connect. Procurement Magazine -This edition offers a preview of Procurement & Supply
More news about: BizClik Media
Sep 10, 2025, 07:00 ET Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed
More news about: Karyopharm Therapeutics Inc.
Sep 03, 2025, 17:31 ET Myelofibrosis Market is Going to Grow at a CAGR of 9% in the Next Ten Years (2025-2034) | DelveInsight
landscape Beyond JAK inhibitors, active clinical development includes BET inhibitors (Incyte's INCB057643; Novartis' Pelabresib), XPO1 inhibitor (Karyopharm Therapeutics' XPOVIO), Telomerase inhibitor (Geron's RYTELO), MDM2 protein inhibitor (Kartos Therapeutics' Navtemadlin),
More news about: DelveInsight Business Research, LLP
Sep 02, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory
More news about: Karyopharm Therapeutics Inc.
Aug 27, 2025, 09:15 ET Human-Centered, Tech-Enabled: Staffmark Group Adopts Bullhorn Recruitment Cloud to Deliver More Value for Clients
Group has delivered the industry's widest range of tailored workforce solutions through its family of specialty brands, including Staffmark, Advantage xPO, Advantage Technical, Hunter Hamilton, and Digital People. Operating across a network of over 400 branches and 250 onsite
More news about: Staffmark Group
Aug 18, 2025, 09:00 ET RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420-429.2. IQVIA XPO Data on file.3. Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori
More news about: RedHill Biopharma Ltd.
Aug 11, 2025, 07:30 ET Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed
More news about: Karyopharm Therapeutics Inc.
Aug 05, 2025, 07:00 ET Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received
More news about: Karyopharm Therapeutics Inc.
Aug 01, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received
More news about: Karyopharm Therapeutics Inc.
Jul 08, 2025, 09:00 ET Percheron Capital Announces Formation of Commercial HVAC Service Platform Led by Accomplished Industry Executive Katrina Liddell
organic growth and successfully executing and integrating high-quality acquisitions. Previously, Katrina held various senior leadership positions at XPO Logistics and Johnson Controls, a leading national provider of commercial HVAC services, where she led one of the company's largest and most successful
More news about: Percheron Capital
Jul 01, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received
More news about: Karyopharm Therapeutics Inc.